Abchurch is pleased to announce it has secured the Financial and Corporate PR brief for SalvaRx, a biotech company focused on therapies that leverage the immune system to fight cancer, following its recent successful reverse takeover of 3Legs Resources on AIM.
Immunotherapy is a fast growing and new therapeutic area within oncology. SalvaRx's strategy is to acquire and invest in a portfolio of companies involved in novel cancer immunotherapies. The Company acquired iOx technologies in 2015, a spin-out from Oxford University, and is currently preparing to take its lead compound through to Phase I/II clinical trials.
Julian Bosdet, Senior Partner of Abchurch, commented: “Abchurch is delighted to have been appointed by SalvaRx. The team is looking forward to working alongside the Company and its advisors to communicate the story to City audiences. Cancer immunotherapy is at the forefront of modern cancer treatment. We look forward to enhancing and supporting SalvaRx’s progress as it moves forward with its pipeline of promising immunotherapy candidates.”
Tel: +44 (0)20 7398 7701